This technology is a monoclonal antibody which binds annexin for the inhibition of Funsobacterium nucleatum (Fn) invasion and proliferation to treat and prevent Fn related diseases including colorectal cancer and Familial Adenomatous Polyposis (FAP).
Funsobacterium nucleatum (Fn) is a commensal bacterium whose presence has been associated with a spectrum of human diseases, such as colorectal cancer or Familial Adenomatous Polyposis. Fn can be targeted with current antibiotics, but this therapeutic strategy disrupts the entire human microbiome. There is a need for therapeutics specifically targeting Fn infection, and preventing diseases associated with Fn presence.
This technology is a monoclonal antibody which binds annexin AI and inhibits binding of Funsobacterium nucleatum (Fn) to host cells. This antibody can therefore serve as a targeted antibiotic against Fn infection. Targeted blocking of Fn invasion and proliferation could be useful as a next-generation prevention and treatment method of Fn-mediated diseases.
This technology has been validated with colorectal cancer cells in vitro.
Patent Pending (WO/2022/16672)
IR CU21260, CU21261
Licensing Contact: Jerry Kokoshka